{"entity":{"id":"paper-jonna-nrg1-fusions-solid-tumours-ccr-2019","kind":"paper","name":"Detection of NRG1 gene fusions in solid tumors","aka":[],"tldr":"Running an RNA-based fusion test across nearly 22,000 tumours of every kind found this rare but treatable fusion in about one in five hundred, most often in lung cancer, and with a different partner gene almost every time.","summary":"Tumour specimens submitted for molecular profiling that underwent fusion testing by anchored multiplex polymerase chain reaction for targeted RNA sequencing were retrospectively reviewed. Of 21,858 specimens profiled between September 2015 and December 2018, 41 cases, 0.2%, harboured an NRG1 fusion, with multiple distinct fusion partners. Fusions occurred across tumour types; the greatest number was in non-small-cell lung cancer, 25 cases, although this represented only 0.3% of the lung cancers tested. Gallbladder, renal cell, bladder, ovarian, pancreatic, breast, neuroendocrine, sarcoma and colorectal cases were also identified.","asOf":"2026-09-25","links":[{"label":"Jonna et al., Clin Cancer Res 2019: NRG1 fusions in 41 of 21,858 solid tumours profiled by RNA sequencing","url":"https://doi.org/10.1158/1078-0432.CCR-19-0160"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/30988082/"}],"tags":[],"related":[],"cancers":["nsclc"],"sections":[],"technologies":["rna-seq","cgp"],"targets":["nrg1","her2"],"drugs":[],"companies":[],"institutions":[],"pathways":["rtk-activation"],"terms":["gene-fusion","tumour-agnostic"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["clinical-cancer-research"],"dependsOn":[],"notes":[],"journal":"Clinical Cancer Research","year":2019,"doi":"10.1158/1078-0432.CCR-19-0160","pmid":"30988082","authors":"Jonna S, Feldman RA, Swensen J, et al.","paperType":"observational","findings":["NRG1 fusions in 41 of 21,858 tumours, 0.2%.","Lung cancer had the highest count, 25 cases, and a rate of 0.3%.","Fusion partners were highly heterogeneous.","Fusions were found across many solid tumour types."],"whatItMeans":"It put a number on how rare NRG1 fusions are and showed that heterogeneous partners make RNA-based testing the only reliable way to find them, which is the practical argument for adding a fusion panel to a driver-negative lung cancer work-up.","caveats":["A commercial testing stream, so the population is selected by who was sent for profiling.","No treatment outcomes.","RNA-based detection requires adequate RNA, which small biopsies often lack."],"changedPractice":false,"participants":21858},"route":"/key-papers/paper-jonna-nrg1-fusions-solid-tumours-ccr-2019/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"technology":[{"id":"cgp","kind":"technology","name":"Comprehensive genomic profiling","route":"/technologies/cgp/"},{"id":"rna-seq","kind":"technology","name":"RNA sequencing & expression profiling","route":"/technologies/rna-seq/"}],"target":[{"id":"her2","kind":"target","name":"HER2","route":"/targets/her2/"},{"id":"nrg1","kind":"target","name":"NRG1","route":"/targets/nrg1/"}],"pathway":[{"id":"rtk-activation","kind":"pathway","name":"Receptor tyrosine kinase activation","route":"/pathways/rtk-activation/"}],"term":[{"id":"gene-fusion","kind":"term","name":"Gene fusion","route":"/terms/gene-fusion/"},{"id":"tumour-agnostic","kind":"term","name":"Tumour-agnostic (tissue-agnostic) approval","route":"/terms/tumour-agnostic/"}],"journal":[{"id":"clinical-cancer-research","kind":"journal","name":"Clinical Cancer Research","route":"/journals/clinical-cancer-research/"}],"biomarker":[{"id":"nrg1-fusion","kind":"biomarker","name":"NRG1 gene fusion","route":"/biomarkers/nrg1-fusion/"}]}}